Qureight and biopharmaceutical company Remedy Cell have agreed a partnership to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF). 

The primary objective of the RC-0315 Phase Ib clinical study is to measure drug safety and tolerability.  

The study’s exploratory objectives will assess the effect of RC-0315 on disease pathology, measured through imaging and biomarker analysis in bronchoalveolar lavage (BAL) and plasma samples. 

RC-0315’s therapeutic effect is attributed to its multi-target approach which enables a regenerative solution for complex fibrotic conditions. 

RC-0315 is a novel multifactorial, multi-proteinacious therapy that hits multiple IPF-associated targets simultaneously. It works by identifying several active proteins that hit relevant lung-tissue molecular targets.  

The effect of hitting these molecular targets results in Ligand-Receptor Interactions, which is thought to be the basis of the treatment’s regenerative mechanism  

Integrating their deep-learning technology in the clinical phase study, Qureight will be providing full end-to-end imaging core lab services, including site qualification, data handling, quality control and deep learning AI image analysis.  

RC-0315 has a novel application, and it will be instilled directly into a chosen lung segment by bronchoscopy. 

Ayelet Dilion Mashiah, CEO, Remedy Cell, said: “Remedy Cell has made significant strides bringing its proprietary technology from bench to clinical trials. We are so pleased to work with Qureight to allow a deeper understanding of RC-0315’s mechanism of action, and to bring further value to our Phase Ib trial.” 

More precise assessment of RC-0315

Qureight will apply its AI modelling techniques to sub-sections of the lungs and look for localised changes in airways, fibrosis and blood vessels. This novel approach offers a more detailed precision-focused quantification of lung segments.  

These insights have the potential to provide crucial data for evaluating the efficacy of RC-0315 and, ultimately, drive progress toward more effective IPF treatments. 

Dr Muhunthan Thillai, CEO, Qureight, said: “Qureight’s AI-driven imaging analysis will allow a more precise assessment of RC-0315’s efficacy, providing the level of detail needed to understand the effects, and map this to patient outcomes. By focusing on localised changes within sub-sections of the lungs, we can move beyond traditional whole-lung assessments and gain a deeper understanding of the treatment’s impact on airways, fibrosis, and blood vessels. This can accelerate the development of more effective therapies for IPF patients.”

Diana Spencer, Senior Digital Content Editor, DDW